Real-world evidence

Caporusso et al case series1

In real-world patients (retrospective case series), NuShield® was used in a wide variety of wounds (N=50), including VLUs (n=14), DFUs (n=24), and other wounds (pressure ulcers, nonhealing surgical, ischemic, mixed etiology, and nonhealing amputation; n=12).1

DFU=diabetic foot ulcer; VLU=venous leg ulcer

Median time to wound closure1

Estimated median time to complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). *All wounds includes DFUs, VLUs, and other wounds. Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wound; 1 nonhealing amputation; and 1 not identified.1

Percentage of wounds closed by week1

Estimated frequency of complete wound closure for wounds from a Cox regression model with terms for age, sex, wound type, wound duration, baseline wound area, and duration in clinic. Test of equality over strata: P=0.071 (Wilcoxon). *All wounds includes DFUs, VLUs, and other wounds. Other includes 3 pressure injuries; 4 nonhealing surgical, 1 ischemic, and 1 mixed etiology wound; 1 nonhealing amputation; and 1 not identified.1

Of those wounds that did not achieve wound closure, 9 (18%) had >90% wound closure, and 8 (16%) had wound closures ranging from 60% to 90% by the last observation.1

Get more growth factors with NuShield

See the results comparing NuShield to another commercially available dHACM, or talk to an Organogenesis Tissue Regeneration Specialist about the dehydrated placental allograft wound covering that retains all native layers.

Contact us

REFERENCE:

  1. Caporusso J, et al. Wounds. 2019;31(4 Suppl):S19-S27.